Approval to vaccines 'turning point' in India's fight against COVID-19: NITI Aayog

NITI Aayog member VK Paul on Sunday said the speed with which scientists and the industry came together to meet this challenge epitomizes the spirit and potential of 'Aatmanirbhar Bharat'.

Published: 03rd January 2021 05:59 PM  |   Last Updated: 03rd January 2021 05:59 PM   |  A+A A-

NITI Aayog

NITI Aayog. (File Photo | PTI)

By PTI

NEW DELHI: Terming the approval given to two coronavirus vaccines for emergency use as "turning point" in India's fight against COVID-19, NITI Aayog member VK Paul on Sunday said the speed with which scientists and the industry came together to meet this challenge epitomizes the spirit and potential of 'Aatmanirbhar Bharat'.

India's drug regulator DCGI on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.

"Today is a turning point in India's fight against Covid-19 as two Made-in-India vaccines get approval for emergency use. The speed with which our scientists and industry came together to meet this challenge, epitomizes the spirit and potential of Aatmanirbhar Bharat," the NITI Aayog said in a tweet quoting Paul, who is also the Chairman of National Expert Group on Vaccine Administration.

The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

"After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation," DCGI Dr VG Somani told a press conference here.

This paves the way for the roll out of at least two vaccines in India in the coming days. The Serum Institute of India, the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield.

Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). Serum Institute of India's CEO Adar Poonawalla tweeted, "Happy new year, everyone! All the risks Serum Institute of India took with stockpiling the vaccine, have finally paid off. COVISHIELD, India's first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks."

Somani said that the authority also granted Cadila Healthcare the permission to conduct the Phase III clinical trial of its vaccine candidate in India

Now we are on Telegram too. Follow us for updates
India Matters

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

Videos
Gallery